Laser light at home could ease nerve pain in feet

NCT ID NCT06912646

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a portable laser device that people use at home to temporarily relieve foot pain caused by idiopathic peripheral neuropathy. 32 adults with constant foot pain for at least 3 months will use the device twice daily for 21 days. The main goal is to see if at least 30% of participants report a meaningful reduction in pain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Erchonia EVRL handheld laser device (red and violet light)

What this could lead to

If it works, this could provide a drug-free option for temporary relief of nerve pain in the feet.

What could go wrong

This is a small, early-stage trial with only 32 people. The effect may be modest or no better than a placebo, and long-term benefits are unknown.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROPATHY;PERIPHERAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic idiopathic neuropathy neuritis peripheral nervous system disorder peripheral neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Franco & Co

    RECRUITING

    Miramar, Florida, 33025, United States

    Contact Email: •••••@•••••